Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALAD: Valacyclovir in Alzheimer's Disease
NCT03282916Phase 2Completed
- Sponsor
- Columbia University
- Start
- Feb 2018
- Primary completion
- Sep 2024
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of valaciclovir in Alzheimer's disease (AD), sponsored by Columbia University. Started Feb 2018; status: completed.
02
Drugs
valaciclovir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03282916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282916.